LATS1 and neoplasm: LATS1/2 loss in these studies [271] enhances tumour immunogenicity, which promotes anti-tumor immune responses and tumour regression leading to a reduction in tumorigenicity invivo [271], suggesting that the Hippo pathway plays a complex role in the involvement of the immune response to oncogenesis.